Heart valve shape may predict drug success in thick heart muscle disease

NCT ID NCT07716826

Not yet recruiting Knowledge-focused Sponsor: French Cardiology Society Source: ClinicalTrials.gov ↗

First seen Jul 21, 2026 · Last updated Jul 22, 2026 · Updated 1 time

Summary

This study looks at people with obstructive hypertrophic cardiomyopathy — a condition where the heart muscle is abnormally thick and blocks blood flow. Researchers want to see if certain abnormalities in the mitral valve or its supporting structures affect how well the drug mavacamten works. Participants are already taking mavacamten, and the study tracks changes in heart pressure and symptoms over six months.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: mavacamten
What this could lead to: If successful, this study could help doctors predict which patients with obstructive hypertrophic cardiomyopathy will benefit most from mavacamten based on their mitral valve anatomy.
What could go wrong: This is an observational study, not a controlled trial, so it cannot prove cause and effect. Results may not apply to all patients with this condition.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates